PERRIGO Co plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PERRIGO Co plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jun 29, 2013 | $800.0K | Aug 13, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.37B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.66B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.45B | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $1.07B | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $4.14B | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $1.01B | May 11, 2022 |
| FY2020 | Dec 31, 2020 | $1.29B | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $1.21B | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $1.22B | Mar 1, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $1.33B | May 22, 2017 |
| FY2016 | Oct 1, 2016 | $1.26B | May 22, 2017 |
| FY2016 | Jul 2, 2016 | $1.34B | May 22, 2017 |
| FY2016 | Apr 2, 2016 | $1.35B | May 22, 2017 |
| FY2016 | Dec 31, 2015 | $1.36B | May 22, 2017 |
| FY2016 | Sep 26, 2015 | $1.27B | May 22, 2017 |
| FY2016 | Jun 27, 2015 | $1.42B | May 22, 2017 |
| FY2016 | Mar 28, 2015 | $967.20M | May 22, 2017 |
| FY2016 | Dec 27, 2014 | $985.10M | May 22, 2017 |
| FY2016 | Sep 27, 2014 | $859.60M | May 22, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.68B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.46B | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $337.80M | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $1.42B | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $368.40M | May 11, 2022 |
| FY2020 | Dec 31, 2020 | $469.20M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $428.10M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $434.70M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.43B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($171.80M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($12.70M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($140.60M) | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | ($2.40M) | May 11, 2022 |
| FY2023 | Dec 31, 2021 | ($68.90M) | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $38.10M | May 11, 2022 |
| FY2020 | Dec 31, 2020 | ($175.00M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($154.60M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $60.60M | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.12B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $112.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $151.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $78.90M | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $21.70M | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $410.40M | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $51.40M | May 11, 2022 |
| FY2022 | Dec 31, 2020 | $265.20M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $174.70M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $236.50M | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $112.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $122.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $123.10M | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $29.30M | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $122.00M | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $31.10M | May 11, 2022 |
| FY2022 | Dec 31, 2020 | $121.70M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $119.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $218.60M | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $362.90M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $405.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $307.30M | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $79.10M | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $156.30M | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $200.0K | May 11, 2022 |
| FY2022 | Dec 31, 2020 | $636.20M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $387.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $593.00M | Mar 1, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $118.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $101.70M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $96.40M | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $20.30M | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $152.10M | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | $45.40M | May 11, 2022 |
| FY2022 | Dec 31, 2020 | $170.40M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $137.70M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $102.60M | Mar 1, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.54B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.65B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $10.81B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $11.02B | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $10.39B | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $10.43B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $11.49B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $11.30B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $10.98B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $11.63B | Feb 27, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.60B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.33B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.04B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $6.18B | Feb 27, 2024 |
| FY2022 | Apr 2, 2022 | $5.29B | May 11, 2022 |
| FY2022 | Dec 31, 2021 | $5.27B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $5.83B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $5.50B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $5.32B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.46B | Feb 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.94B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.77B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $4.84B | Feb 26, 2026 |
| FY2022 | Apr 2, 2022 | $5.10B | May 11, 2022 |
| FY2024 | Dec 31, 2021 | $5.15B | Feb 28, 2025 |
| FY2022 | Apr 3, 2021 | $5.56B | May 11, 2022 |
| FY2023 | Dec 31, 2020 | $5.66B | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $5.80B | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $5.67B | Mar 1, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.53B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.49B | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | $2.97B | May 11, 2022 |
| FY2023 | Dec 31, 2021 | $3.00B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $3.10B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $3.10B | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $3.98B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $4.18B | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.68B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.25B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.08B) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($2.07B) | Feb 27, 2024 |
| FY2022 | Apr 2, 2022 | ($1.93B) | May 11, 2022 |
| FY2022 | Dec 31, 2021 | ($1.93B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.86B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.70B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($1.84B) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($1.98B) | Feb 27, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $600.70M | Feb 28, 2023 |
| FY2022 | Apr 2, 2022 | $1.97B | May 11, 2022 |
| FY2022 | Dec 31, 2021 | $1.86B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $631.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $354.30M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $551.10M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $678.70M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $622.30M | Feb 27, 2019 |
| FY2018 | Dec 31, 2015 | $417.80M | Feb 27, 2019 |
| FY2016 | Jun 27, 2015 | $785.60M | May 22, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jun 27, 2015 | $820.90M | Aug 13, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (10) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | 0 | May 11, 2022 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | 0 | May 11, 2022 |
| FY2020 | Dec 31, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (10) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2022 | Apr 2, 2022 | 0 | May 11, 2022 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Apr 3, 2021 | 0 | May 11, 2022 |
| FY2020 | Dec 31, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | (1) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 137.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 136.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 135.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 134.70M | Feb 27, 2024 |